Blair William & Co. IL Cuts Stock Holdings in Zoetis Inc. $ZTS

Blair William & Co. IL decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 28.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 969,963 shares of the company’s stock after selling 393,192 shares during the period. Blair William & Co. IL’s holdings in Zoetis were worth $122,041,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ZTS. Brighton Jones LLC grew its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC boosted its holdings in Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC boosted its holdings in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Zoetis by 73.8% in the second quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co boosted its holdings in Zoetis by 11.8% in the second quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: The flood of class-action reminders highlights alleged investor harm and creates another headline risk for Zoetis, which can weigh on sentiment while litigation moves forward. Article Title
• Negative Sentiment: Several law firms allege securities-law violations tied to the same class period, reinforcing uncertainty around prior disclosures and potentially keeping pressure on the stock. Article Title
• Neutral Sentiment: The company’s recent earnings backdrop remains a separate concern: Zoetis previously missed both EPS and revenue estimates, which may continue to influence investor caution.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ZTS shares. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. BTIG Research restated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. UBS Group dropped their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Finally, Weiss Ratings cut shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average target price of $133.92.

Insider Transactions at Zoetis

In other Zoetis news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the purchase, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is currently owned by insiders.

Zoetis Trading Down 0.8%

Shares of Zoetis stock opened at $79.28 on Wednesday. The company’s fifty day simple moving average is $95.41 and its 200-day simple moving average is $113.49. The stock has a market capitalization of $33.24 billion, a PE ratio of 13.15, a P/E/G ratio of 1.25 and a beta of 0.75. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $164.32. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.